Delivery Order SPE2DB20D6035-SPE2DB25FLYEM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,627.40 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 18, 2025, with completion scheduled for August 19, 2025. This firm fixed-price, competitively awarded contract with no set-aside designation leverages AmerisourceBergen's position as a major pharmaceutical distributor supporting federal medical procurement. The work will be performed at the company's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $14,221.61 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on September 22, 2025, with final delivery required by September 23, 2025. This non-competitive delivery order utilizes firm fixed-price pricing and represents a routine pharmaceutical supply transaction under the company's existing contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $3,096.32 delivery order to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 22, 2025, with an ultimate completion date of August 25, 2025. This is a firm fixed-price, non-competitive delivery order with no set-aside designation. The pharmaceutical products will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, which serves as the company's corporate office and primary distribution hub for...
- The Defense Logistics Agency awarded a delivery order valued at $73,229.67 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 13, 2025, with completion targeted for August 14, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract fulfilling federal pharmaceutical procurement requirements. The award was placed to AmerisourceBergen's Corporate Office located in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $24,643.14 to supply BIKTARVY 50-200-25 mg tablets (30-count units) with a firm fixed price structure and completion date of September 10, 2025. This non-set-aside, competitively awarded contract represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply relationship with the federal government. The place of performance is the company's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $31,905.60 on August 1, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with an ultimate completion date of August 4, 2025, and represents a non-competitive set-aside award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major...
- The Defense Logistics Agency awarded a delivery order valued at $18,061.50 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed price contract with no set-aside designation, competitively awarded to support federal pharmaceutical procurement. The order was executed on June 18, 2025, with an ultimate completion date of June 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $63,657.20 delivery order to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) with an ultimate completion date of August 14, 2025. This competitive delivery order, issued with firm fixed pricing and no set-aside designation, represents a single transaction under AmerisourceBergen's larger federal pharmaceutical supply framework. The award specifies Conshohocken, Pennsylvania as the place of performance, aligning with...
- The Defense Logistics Agency awarded a delivery order valued at $5,533.31 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) with a firm fixed price structure. The award was made on August 5, 2025, with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This delivery order is...
- The Defense Logistics Agency awarded a $13,501.58 delivery order to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count unit doses) on October 23, 2025, with an ultimate completion date of October 24, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, fulfilling pharmaceutical supply requirements for federal military and healthcare systems. The product will be delivered to AmerisourceBergen's place of performance in...
- SPE2DB20D6035Indefinite Delivery Contract
- SPE2DB20D6035-SPE2DB25FLYEMDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $28,781.38 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a pharmaceutical supply requirement fulfilled from AmerisourceBergen's existing contract vehicle. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery order draws from AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates consistent capability to meet DLA procurement requirements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical supplies supporting the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $28.8k | 8/4/25 |